ODTC Company Profile and Key Details

Q: Who are the executives of ODTC?

Mr. Thomas WeiChief Scientific OfficerMs. Tracey McKennonSenior Vice President of Quality AssuranceMr. Michael S. HearneChief Financial Officer & Principal Accounting OfficerMs. Kim MaSenior Vice President of Clinical OperationsMr. Stewart M. KrollChief Devel. OfficerMr. Kevin C. TangChairman & Chief Executive OfficerMr. Ryan ColeSenior Vice President of OperationsDr. Steven S. Pfeiffer Ph.D.Senior Vice President of Technical OperationsMs. Jennifer SchroederSenior Vice President of Clinical Devel. Operations

PNK : ODTC

Odonate Therapeutics

$2,849.50

At Close 4:00 PM

Not Actively Trading

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Odonate Therapeutics, Inc. (ODTC) stock surged +29.44%, trading at $22,005.00 on OTC, up from the previous close of $17,000.00. The stock opened at $22,005.00, fluctuating between $22,005.00 and $22,005.00 in the recent session.

Stock Snapshot

17000

Prev. Close

8.05B

Market Cap

22005

Day Low

1.0692419825072885

P/E Ratio

20580

EPS (TTM)

-6911.45

Cash Flow per Share

22.01K

Open

365.65K

Number of Shares

22005

Day High

1,231,555.84%

Free Float in %

8285.86

Book Value

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close
Feb 11, 2025	150,000.00	150,000.00	150,000.00	150,000.00
Feb 07, 2025	150,000.00	150,000.00	150,000.00	150,000.00
Feb 05, 2025	150,000.00	150,000.00	150,000.00	150,000.00
Feb 03, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 31, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 30, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 29, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 28, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 27, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 24, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 23, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 22, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 21, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 17, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 16, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 15, 2025	176,040.00	176,040.00	176,040.00	176,040.00
Jan 14, 2025	164,000.00	176,040.00	164,000.00	176,040.00
Jan 13, 2025	136,000.00	136,000.00	136,000.00	136,000.00
Jan 10, 2025	136,400.00	136,400.00	136,400.00	136,400.00
Jan 08, 2025	136,400.00	136,400.00	136,400.00	136,400.00

Contact Details

New York City, NY 10016

United States

https://www.odonate.com 332 206 0935

About Company

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.

Stock Peers

GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 FNCH

-0.05-0.38%

Finch Therapeutics Group, Inc.$13.20 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

The stock is currently trading near its 52-week low $22.00 thousand and $358.00 thousand. With a market capitalization of about $8.05 billion, Odonate Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.17). Headquartered in New York City, NY, Odonate Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kevin C. Tang, the company employs approximately 137 people and listed since December 07, 2017. Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.

Valuation Metrics

Odonate Therapeutics, Inc. trades at a P/E ratio of 3227.3, slightly above the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 218.64 reflecting a rich premium to book value. The P/FCF stands at 920.61, also above market averages. Compared to sector medians, Odonate Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Odonate Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $12.98. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Odonate Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended July 27, 2021, missed forecasts by 75.76%. The prior quarter beat by 11.11%. Over the last six quarters, Apple has recorded several small beats. These include -2.94% in April 28, 2020.

Shareholding & Insider Activity

Odonate Therapeutics, Inc. has 356.00 shares outstanding. The public float is 35.14 million shares, elevated short interest at 2.31% of float. This equals 4.00 shares. The short ratio is 0.59 days.

Financial & Profitability Overview

Over the trailing twelve months, Odonate Therapeutics has not generated any revenue. Returns are negative, with ROA at -75.26% and ROE at -92.81%.
On valuation metrics, Odonate Therapeutics trades at a P/E of 3227.30, P/S of 0.00 and P/B of 218.64. The current ratio is 111.72 and quick ratio is 111.72. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -34.76 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of 3.80.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2020, Odonate Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $127.43M (margin 0.0%). Net income was- $126.35M (EPS - $3.84).
The company ended the quarter with $157.27M in cash and short-term investments, a total debt of $5.33M, and net debt of - $151.94M. Total assets were $167.89M, with equity of $136.15M. Financials further reflected weakness, with operating cash flow of - $113.13M, free cash flow of - $113.56M, and capital expenditures of - $432.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Odonate Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Odonate Therapeutics, Inc. trading at a premium to the broader market with a P/E of 3227.3.

Frequently Asked Questions

What is the current Odonate Therapeutics, Inc. (ODTC) stock price?

Odonate Therapeutics, Inc. (OTC: ODTC) stock price is $22,005.00 in the last trading session. During the trading session, ODTC stock reached the peak price of $22,005.00 while $22,005.00 was the lowest point it dropped to. The percentage change in ODTC stock occurred in the recent session was 29.44% while the dollar amount for the price change in ODTC stock was $5,005.00.

ODTC's industry and sector of operation?

The OTC listed ODTC is part of Biotechnology industry that operates in the broader Healthcare sector. Odonate Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ODTC?

Mr. Thomas Wei
Chief Scientific Officer
Ms. Tracey McKennon
Senior Vice President of Quality Assurance
Mr. Michael S. Hearne
Chief Financial Officer & Principal Accounting Officer
Ms. Kim Ma
Senior Vice President of Clinical Operations
Mr. Stewart M. Kroll
Chief Devel. Officer
Mr. Kevin C. Tang
Chairman & Chief Executive Officer
Mr. Ryan Cole
Senior Vice President of Operations
Dr. Steven S. Pfeiffer Ph.D.
Senior Vice President of Technical Operations
Ms. Jennifer Schroeder
Senior Vice President of Clinical Devel. Operations

How ODTC did perform over past 52-week?

ODTC's closing price is 37,893.33% higher than its 52-week low of $22,005.00 where as its distance from 52-week high of $358,000.00 is -94.29%.

How many employees does ODTC have?

Number of ODTC employees currently stands at 137.

Link for ODTC official website?

Official Website of ODTC is: https://www.odonate.com

How do I contact ODTC?

ODTC could be contacted at phone 332 206 0935 and can also be accessed through its website. ODTC operates from 3 East 28th Street, New York City, NY 10016, United States.

How many shares of ODTC are traded daily?

ODTC stock volume for the day was 1 shares. The average number of ODTC shares traded daily for last 3 months was 0.

What is the market cap of ODTC currently?

The market value of ODTC currently stands at $8.05B with its latest stock price at $22,005.00 and 365.65K of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	137
Beta	0.17
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ODTC Company Profile and Key Details

Odonate Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics